CCR3 activation is reported to be essential for in vivo angiogenesis in a preclinical model of age-related macular degeneration and neutralization by CCR3 antibodies inhibited the tube formation of primary human circulating endothelial cells in vitro54, demonstrating consistent results of our present study. The gene discussed is CCR3; the disease is age-related macular degeneration.